Navigation Links
Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
Date:5/22/2012

LEXINGTON, Mass., May 22, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company was awarded U.S. Patent 8,182,818, entitled "Methods of Using Anti-TNF Antibodies for Treating Radiation Damage to the Digestive Tract."

This patent provides broad coverage for using topically administered anti-TNF antibodies to treat radiation induced damage to the digestive tract.  Importantly, the patent specifically covers treatment of radiation induced mucositis, which is a common side effect of radiation therapy for cancer that often limits the effective radiation dose a patient can tolerate.  Avaxia has active research and development programs for its oral antibody AVX-470 for use in gastrointestinal acute radiation syndrome (GI-ARS) and mucositis. 

"This new patent emphasizes the innovative nature and broad applicability of our AVX Oral Antibody technology platform," stated Barbara Fox, PhD, CEO of Avaxia.  "For many cancer patients, the side effect of mucositis becomes intolerable, which causes terrible discomfort and may limit the dose of radiation that the patient receives to fight the disease.  Also, effective treatments for radiation damage are an important need for responding to potential terrorist attacks involving radioactive substances. Much of the morbidity and mortality associated with total body irradiation is due to damage to the GI tract. We are actively working to prove that AVX-470 can reduce that damage."

Avaxia has a $2.9 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop its oral anti-TNF antibody, AVX-470, for GI ARS. The work under this current contract explores the potential for the antibody to be further developed into a medical countermeasure to mitigate gastrointestinal damage from radiation exposure.

About Avaxia Biologics, Inc.: Avaxia is developing orally administered antibody therapeutics that act locally within the gastrointestinal (GI) tract.  Antibodies are widely used as therapeutics, with nearly $50 billion in annual sales worldwide.  Ordinary antibodies are not administered orally because they are destroyed in the GI tract.  In contrast, Avaxia has developed proprietary antibodies that are stable in the GI tract.  AVX Oral Antibodies make diseases with targets in the GI tract accessible to antibody therapeutics for the first time.  Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes, and obesity. 


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
2. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
3. Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
4. Avaxia Biologics Barbara Fox Named one of Mass High Techs Women to Watch in 2012
5. Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease
6. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
7. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
8. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
9. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
10. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
11. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016 ... for the treatment of cancer and orphan genetic diseases, ... up to $4.4 million from the Israel Innovation Authority ... Israeli Ministry of Economy and Industry. The mission of ... entrepreneurship in various industries, including science and technology, while ...
(Date:5/23/2016)... May 23, 2016   Purdue Pharma L.P. ... an agreement with Egalet Corporation and Acura Pharmaceuticals, ... part of the agreement the companies will exchange ... all three companies to develop and sell several ... "This agreement reflects the commitment of Purdue Pharma ...
(Date:5/20/2016)... , May 20, 2016 ... 2016 to Medical Devices of its online business ... survey on the current state of the Titrator ... the industry like definitions, classifications, Specifications, applications and ... manufacturing process like Raw Material Suppliers, Equipment Suppliers, ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... Regenerative Medicine is being transformed by ongoing ... therapy technology, protocols and patient results as have been achieved with Okyanos Cell ... accessible standard of care for patients worldwide. , As the Medical Advisory Chairman at ...
(Date:5/24/2016)... New York, NY (PRWEB) , ... May 24, ... ... of rehabilitative treatment for physical disease or injury that focuses on repairing the ... surgery. , With an emphasis on functional restoration, NYDNRehab began providing treatments ...
(Date:5/24/2016)... ... ... A newly released report reveals that improving life outcomes for boys and men ... interactions and online. In “Heard, Not Judged – Insights into the Talents, Realities and ... digital devices can be an effective tool to help boys and men of color ...
(Date:5/24/2016)... ... May 24, 2016 , ... The ... clinical practice of radiosurgery, is recognizing five medical residents and students for their ... body radiotherapy (SBRT). The awards will be presented at the 2016 SRS/SBRT Scientific ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Tuesday, May ... , The Yoga practice enhanced with Young Living Essential Oils, taught by Patti Dolan, ... at the Lake Orion location. Yoga Flow is 6:30pm - 7:15pm followed by a ...
Breaking Medicine News(10 mins):